This article needs ACTIVE NOTEBOOK BTS 2 PDF medical references for verification or relies too heavily on primary sources. Methcathinone was first synthesized in 1928 in the United States and was patented by Parke Davis in 1957. In parts of Europe this drug is not listed as a dangerous drug and is under review by the authorities in the United Kingdom where at the moment it is a Class B drug.
They want it reclassified as a class A drug when it is dissolved in water for injection use just as amphetamine is. This section needs additional citations for verification. Methcathinone is a beta-keto N-methylamphetamine and is closely related to the naturally occurring compounds, cathinone and cathine. Methcathinone possesses a chiral carbon atom, and therefore two enantiomers are possible.
Methcathinone production utilizes the oxidation of pseudoephedrine or ephedrine, the former being preferred because of much higher yields achieved. In clandestine laboratories, synthesizing methcathinone using potassium permanganate is considered undesirable because of the low yields and the high toxicity of this oxidant, however, if done in a proper laboratory using the proper procedures potassium permanganate can be a high-yielding reactant. O bond at the Rβ-position is converted into a C-OH bond. The effects of methcathinone usually last from four to six hours.